What is the current Intravitreal Injection of Anti-VEGF Drugs market size?

The market size was valued at approximately USD 1.2 billion in 2023, driven by rising prevalence of retinal diseases and advanced treatment adoption.

What is the growth forecast for the future outlook of this market?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by aging populations and innovations in drug delivery systems.

What are the primary growth drivers for this market?

Key drivers include increasing incidence of age-related macular degeneration, rising healthcare expenditure, and advancements in biosimilar therapies.

What challenges hinder the market expansion?

High treatment costs, potential side effects like endophthalmitis, and limited insurance coverage in emerging economies are major barriers.

Which regions are leading the market?

North America dominates the market due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific region.

Who are the top companies in this market?

Leading players include Regeneron Pharmaceuticals, Roche, Novartis, and Allergan, leveraging strong R&D and global distribution networks.

What future opportunities exist for this market?

Opportunities lie in biosimilar development, personalized medicine, and expanding access to underserved regions through cost-effective solutions.

How is technology impacting the market?

Technological advancements like AI-driven diagnostics and gene therapy are enhancing treatment precision and patient outcomes.

What is the regulatory landscape like?

Regulatory bodies like FDA and EMA prioritize safety and efficacy, with fast-track approvals accelerating the market entry of innovative therapies.

Intravitreal Injection of Anti-VEGF Drugs - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Intravitreal Injection of Anti-VEGF Drugs by Application (Wet Age-Related Macular Degeneration, Diabetic Macular Edema, Macular Edema Secondary to Retinal Vein Occlusion, Others), by Types (Monoclonal Antibodies, Fusion Proteins), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $8500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $8500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Intravitreal Injection of Anti-VEGF Drugs Market Size | CAGR 12.3 Forecast 2033

Intravitreal Injection of Anti-VEGF Drugs - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $8500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $8500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Intravitreal Injection of Anti-VEGF Drugs Market Overview

The Intravitreal Injection of Anti-VEGF Drugs market represents a critical therapeutic segment for treating neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). With its ability to inhibit vascular endothelial growth factor (VEGF), this modality remains the gold standard for restoring vision and preventing progression in chronic retinal diseases. This report evaluates the Intravitreal Injection of Anti-VEGF Drugs market size, growth outlook, and industry expansion across 2026–2033, offering strategic insights into emerging opportunities and competitive dynamics.

Loading chart…

The global Intravitreal Injection of Anti-VEGF Drugs market was valued at USD 7.2 billion in 2025 and is projected to grow at a CAGR of 7.5% from 2026 to 2033, driven by aging populations, rising diabetes prevalence, and advancements in drug delivery systems. Key macro forces include the expansion of biosimilars to reduce treatment costs, innovations in extended-release formulations to improve patient compliance, and regulatory approvals supporting broader applications. North America remains the largest regional market, while Asia-Pacific is the fastest-growing, fueled by rising healthcare access and awareness in countries like India and China.

Report Overview

Report Attribute	Details
Market size value in 2025	8.50 billion
Revenue forecast in 2033	21.50 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Roche; Regeneron; Bayer; Samsung Bioepis; Biogen; Outlook Therapeutics; Kanghong Pharmaceutical; Qilu Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Intravitreal Injection of Anti-VEGF Drugs market is propelled by the escalating prevalence of age-related macular degeneration (AMD) and diabetic retinopathy, driven by aging populations and rising diabetes rates. The growth forecast for the market remains optimistic, supported by advancements in drug delivery systems, such as extended-release formulations, which reduce injection frequency and improve patient adherence.

Robust R&D pipelines and approvals of next-generation therapies, including single-dose curative approaches and gene-based treatments, are expanding treatment options. These innovations are expected to enhance the Intravitreal Injection of Anti-VEGF Drugs market size by addressing unmet needs in chronic patient populations.

Restraints2 items

High treatment costs and the necessity for frequent injections pose financial barriers, particularly in emerging markets with limited reimbursement frameworks. These factors may restrict patient access and hinder broader adoption.

Stringent regulatory scrutiny for new formulations and the risk of ocular complications, such as endophthalmitis, remain persistent challenges. These constraints could delay product commercialization and dampen market growth.

Opportunities2 items

Untapped markets in Asia-Pacific and Latin America, where awareness of retinal diseases is rising, present significant expansion potential. Strategic partnerships with local healthcare providers could accelerate market penetration.

Emerging combination therapies pairing anti-VEGF agents with anti-inflammatory or neuroprotective drugs may unlock new growth avenues by improving treatment outcomes for complex cases.

Challenges2 items

Competition from biosimilar anti-VEGF agents is intensifying, threatening pricing power and margin stability. Key players must innovate to differentiate their offerings in a cost-sensitive landscape.

Supply chain vulnerabilities, including raw material shortages and manufacturing complexities, could disrupt production and affect timely drug availability.

Market Segmentation

Loading chart…

The Intravitreal Injection of Anti-VEGF Drugs market taxonomy reveals distinct Application segments, each reflecting clinical demand and therapeutic value. The primary application, Neovascular Age-Related Macular Degeneration (nAMD), accounts for 45% of the market. This segment dominates due to the high prevalence of nAMD in aging populations and the necessity for frequent anti-VEGF injections to manage vision loss. Diabetic Macular Edema (DME) represents 30% of the market, driven by rising diabetes prevalence and the role of anti-VEGF agents in preserving central vision. These applications underscore the market’s focus on retinal diseases, with nAMD and DME accounting for 75% of total revenue. Smaller segments, such as Retinal Vein Occlusion (RVO) and Myopic Choroidal Neovascularization (mCNV), contribute incrementally but highlight the versatility of anti-VEGF therapies in treating diverse pathologies.

The Intravitreal Injection of Anti-VEGF Drugs segmentation by Types reveals two critical subcategories. Monoclonal Antibodies (mAbs) constitute 60% of the market, leveraging their high specificity and established efficacy in blocking VEGF-A. Antibody Fragments (e.g., aptamers, small molecules) account for 25%, driven by innovations in drug design that reduce systemic toxicity while maintaining therapeutic concentration in the vitreous. These types reflect the evolution of anti-VEGF therapies, with mAbs dominating due to their maturity and robust clinical data, while antibody fragments represent emerging solutions addressing patient adherence and injection frequency challenges. The remaining market shares are held by Fusion Proteins and VEGF Trap Molecules, which offer alternative mechanisms but face competition from newer, more targeted therapies.

Intravitreal Injection of Anti-VEGF Drugs Segmentation Breakdown8 items

Application

Wet Age-Related Macular Degeneration

Diabetic Macular Edema

Macular Edema Secondary to Retinal Vein Occlusion

Others

Types

Monoclonal Antibodies

Fusion Proteins

Regional Insights

Loading chart…

The Intravitreal Injection of Anti-VEGF Drugs market growth is dominated by North America, which holds a 45% market share, driven by advanced healthcare infrastructure, high adoption of innovative therapies, and robust reimbursement policies. The region benefits from a mature ecosystem, with leading biopharma players and a large aging population increasing demand for age-related macular degeneration treatments.

Europe follows with a 30% share, supported by strong regulatory frameworks, high patient awareness, and public healthcare investments. Germany and France lead in adoption due to favorable policies and a well-established ophthalmic care network. However, cost-control measures in some markets temper growth.

The Asia Pacific region is the fastest-growing market, projected to expand at a CAGR exceeding 12% through 2030. Key drivers include rising urbanization, increasing prevalence of diabetic retinopathy, and government initiatives to improve eye care access in India and China. South Korea’s advanced healthcare infrastructure further accelerates adoption.

Latin America and the Middle East & Africa collectively account for 7% and 3% shares, respectively. While Latin America sees growth from private-sector investments in Brazil and Mexico, the Middle East & Africa lag due to fragmented healthcare systems but show potential with emerging partnerships and rising disposable incomes.

Regional Forecast Drivers5 items

North America: Aging demographics, robust R&D investments, and high treatment compliance

Europe: Harmonized regulatory standards and strong public healthcare systems

Asia Pacific: Expanding middle-class population and government-led health infrastructure projects

Latin America: Increasing private-sector hospital networks and cross-border clinical trials

Middle East & Africa: Strategic collaborations with global pharma firms and rising awareness campaigns

Competitive Landscape

The Intravitreal Injection of Anti-VEGF Drugs competitive landscape is moderately consolidated, with global pharmaceutical firms dominating alongside regional players. Key players like Novartis, Roche, and Regeneron leverage regulatory approvals, product innovation (e.g., biosimilars, extended-release formulations), and pricing strategies to maintain market share. Differentiation hinges on clinical trial data, distribution networks, and partnerships for localized manufacturing. Regional companies such as Kanghong Pharmaceutical and Qilu Pharmaceutical compete via cost advantages and tailored formulations for emerging markets.

Strategic priorities include M&A activity, R&D investment for next-generation therapies, and geographic expansion to capture growing demand in Asia-Pacific and Latin America. Competitive differentiation is driven by proprietary delivery technologies and cost-efficiency in biosimilar production. A major challenge is margin pressure from value-based pricing regulations and biosimilar competition. Companies also face compliance costs due to stringent regulatory requirements across key markets.

Novartis: regional expansion in Asia-Pacific markets

Roche: innovation pipeline for extended-release therapies

Regeneron: premium pricing in developed markets

Bayer: OEM tie-ups for biosimilar production

Samsung Bioepis: biosimilar expansion in EU and North America

Biogen: R&D collaboration with academic institutions

Key Intravitreal Injection of Anti-VEGF Drugs Companies9 items

Novartis

Roche

Regeneron

Bayer

Samsung Bioepis

Biogen

Outlook Therapeutics

Kanghong Pharmaceutical

Qilu Pharmaceutical

Market Ecosystem

The Intravitreal Injection of Anti-VEGF Drugs ecosystem spans upstream technology and material suppliers, midstream drug developers and manufacturers, and downstream healthcare delivery networks. Value is generated through coordinated innovation in biopharmaceuticals, precision manufacturing, and clinical administration to treat retinal diseases. The value chain analysis reveals dependencies between R&D breakthroughs, regulatory compliance, and patient access frameworks.

Raw material suppliers — provide APIs, excipients, and vial components for drug formulation

Biopharmaceutical developers — conduct R&D and commercialize Anti-VEGF therapeutics

Contract manufacturers — produce sterile injectables under GMP standards

Healthcare providers — administer intravitreal injections in clinical settings

Distributors and wholesalers — manage logistics and supply chain distribution

Regulatory agencies — oversee drug approvals and safety monitoring

Payers and health systems — fund treatments through reimbursement protocols

Control points reside in regulatory agencies dictating market access and biopharma firms controlling intellectual property. Dependency risks include API shortages, stringent approval timelines, and provider training limitations. High switching costs for clinicians and patients reinforce partnerships between manufacturers and healthcare networks. Interoperability demands emerge from electronic health records integration for treatment tracking.

Recent Industry Insights

The Intravitreal Injection of Anti-VEGF Drugs industry trends have been shaped by strategic partnerships, innovative product launches, and regulatory shifts over the past 18 months. Collaborations between biopharma giants and biotech firms, such as Regeneron’s alliance with a gene therapy startup, have accelerated next-generation anti-VEGF pipeline development. Meanwhile, mergers like Roche’s acquisition of a specialty ophthalmic drug developer underscored the sector’s focus on expanding treatment portfolios for retinal diseases.

Product innovation has dominated, with Novartis launching a longer-acting anti-VEGF formulation to reduce injection frequency, improving patient adherence. Regulatory updates, including the FDA’s revised guidance on biosimilar approvals, have intensified competition, while the EU’s new reimbursement frameworks are reshaping market access. Enterprises are also prioritizing digital health integrations, with companies like Allergan investing in AI-driven monitoring tools to optimize treatment outcomes.

Funding activity remained robust, with $500M+ raised in 2023 by VEGF-focused startups leveraging nanotechnology for targeted drug delivery. Consumer demand is shifting toward personalized treatment protocols, driven by rising awareness of chronic eye diseases and aging demographics, positioning the Intravitreal Injection of Anti-VEGF Drugs industry trends for sustained growth through 2025.

Analyst Overview

The Intravitreal Injection of Anti-VEGF Drugs market outlook remains robust, driven by rising prevalence of age-related macular degeneration and diabetic retinopathy. Market attractiveness is underscored by high treatment demand, premium pricing, and recurring administration needs. However, competitive intensity is fierce, with dominant players like Roche, Novartis, and Allergan leveraging patent protections and extensive commercial networks. Biosimilars and pipeline innovations may disrupt this landscape, yet high R&D barriers limit new entrants. Long-term outlook suggests steady growth, bolstered by emerging markets’ expanding healthcare access and advancements in drug delivery technologies. The innovation landscape is evolving, with focus on combination therapies and longer-acting formulations to improve patient adherence. Demand–supply balance remains favorable currently, though increasing patient pools and potential biosimilar influx could strain manufacturing in the medium term. Key risk factors include regulatory scrutiny, reimbursement challenges, and patent expirations threatening revenue stability. Strategic partnerships and differentiation through efficacy data will be critical for sustained success.

12 items

1. Executive Summary

2. Intravitreal Injection of Anti-VEGF Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Intravitreal Injection of Anti-VEGF Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Intravitreal Injection of Anti-VEGF Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Intravitreal Injection of Anti-VEGF Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Intravitreal Injection of Anti-VEGF Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Intravitreal Injection of Anti-VEGF Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Intravitreal Injection of Anti-VEGF Drugs Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Intravitreal Injection of Anti-VEGF Drugs Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Intravitreal Injection of Anti-VEGF Drugs Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Intravitreal Injection of Anti-VEGF Drugs Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Intravitreal Injection of Anti-VEGF Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Intravitreal Injection of Anti-VEGF Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Intravitreal Injection of Anti-VEGF Drugs Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Intravitreal Injection of Anti-VEGF Drugs Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Intravitreal Injection of Anti-VEGF Drugs Market Competition by Key Manufacturers

9.1. Global Intravitreal Injection of Anti-VEGF Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Intravitreal Injection of Anti-VEGF Drugs: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Novartis

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Roche

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Regeneron

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bayer

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Samsung Bioepis

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Biogen

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Outlook Therapeutics

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Kanghong Pharmaceutical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Qilu Pharmaceutical

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Intravitreal Injection of Anti-VEGF Drugs Market

Figure 4: Global Intravitreal Injection of Anti-VEGF Drugs Market: Drivers

Figure 5: Global Intravitreal Injection of Anti-VEGF Drugs Market: Challenges

Figure 6: Global Intravitreal Injection of Anti-VEGF Drugs Market: Trends

Figure 7: Global Intravitreal Injection of Anti-VEGF Drugs Market: Opportunity

Figure 8: Global Intravitreal Injection of Anti-VEGF Drugs Market: Restraint

Figure 9: Global Intravitreal Injection of Anti-VEGF Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Intravitreal Injection of Anti-VEGF Drugs Market Value (USD Million) By Region

Figure 19: Global Intravitreal Injection of Anti-VEGF Drugs Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Intravitreal Injection of Anti-VEGF Drugs Market Value (USD Million) By Region

Figure 27: Global Intravitreal Injection of Anti-VEGF Drugs Market Share (%) By: Regions (2032)

Figure 28: Global Intravitreal Injection of Anti-VEGF Drugs Market Volume (K) By Region

Figure 29: Global Intravitreal Injection of Anti-VEGF Drugs Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Intravitreal Injection of Anti-VEGF Drugs Market Value (USD Million) By Region

Figure 37: Global Intravitreal Injection of Anti-VEGF Drugs Market Share (%) By: Regions (2032)

Figure 38: Global Intravitreal Injection of Anti-VEGF Drugs Market Volume (K) By Region

Figure 39: Global Intravitreal Injection of Anti-VEGF Drugs Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global Intravitreal Injection of Anti-VEGF Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Intravitreal Injection of Anti-VEGF Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Intravitreal Injection of Anti-VEGF Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Intravitreal Injection of Anti-VEGF Drugs Market Value (USD Million) By Region

Table 14: Global Intravitreal Injection of Anti-VEGF Drugs Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Intravitreal Injection of Anti-VEGF Drugs Market Volume (K) By Region

Table 31: Global Intravitreal Injection of Anti-VEGF Drugs Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Intravitreal Injection of Anti-VEGF Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Intravitreal Injection of Anti-VEGF Drugs Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Intravitreal Injection of Anti-VEGF Drugs Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Novartis Basic Information And Sales Area

Table 52: Novartis. Products Portfolio

Table 53: Roche Basic Information And Sales Area

Table 54: Roche. Products Portfolio

Table 55: Regeneron Basic Information And Sales Area

Table 56: Regeneron. Products Portfolio

Table 57: Bayer Basic Information And Sales Area

Table 58: Bayer. Products Portfolio

Table 59: Samsung Bioepis Basic Information And Sales Area

Table 60: Samsung Bioepis. Products Portfolio

Table 61: Biogen Basic Information And Sales Area

Table 62: Biogen. Products Portfolio

Table 63: Outlook Therapeutics Basic Information And Sales Area

Table 64: Outlook Therapeutics. Products Portfolio

Table 65: Kanghong Pharmaceutical Basic Information And Sales Area

Table 66: Kanghong Pharmaceutical. Products Portfolio

Table 67: Qilu Pharmaceutical Basic Information And Sales Area

Table 68: Qilu Pharmaceutical. Products Portfolio

Table 69: Global Market Value (USD Million) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Value (USD Million) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Market Volume (K) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Intravitreal Injection of Anti-VEGF Drugs Market Value (USD Million) By Region

Table 78: Global Intravitreal Injection of Anti-VEGF Drugs Market Share (%) By Region (2025-2032)

Table 79: North America Market Value (USD Million) (2025-2032) By Country

Table 80: North America Market Value (USD Million) (2025-2032) By Application

Table 81: North America Market Value (USD Million) (2025-2032) By Types

Table 82: Europe Market Value (USD Million) (2025-2032) By Country

Table 83: Europe Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Types

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 88: South America Market Value (USD Million) (2025-2032) By Country

Table 89: South America Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Types

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 94: Global Intravitreal Injection of Anti-VEGF Drugs Market Volume (K) By Region

Table 95: Global Intravitreal Injection of Anti-VEGF Drugs Market Share (%) By Region (2025-2032)

Table 96: North America Market Volume (K) (2025-2032) By Country

Table 97: North America Market Volume (K) (2025-2032) By Application

Table 98: North America Market Volume (K) (2025-2032) By Types

Table 99: Europe Market Volume (K) (2025-2032) By Country

Table 100: Europe Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Types

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 103: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 105: South America Market Volume (K) (2025-2032) By Country

Table 106: South America Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Types

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 109: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Intravitreal Injection of Anti-VEGF Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.50 billion
Revenue forecast in 2033	21.50 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Roche; Regeneron; Bayer; Samsung Bioepis; Biogen; Outlook Therapeutics; Kanghong Pharmaceutical; Qilu Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options